All payments made in the preview are in test mode. Read more

Abbott initiates VOYAGER CE trial of Encantor TAVI system

First enrollment marks the start of a study intended to support European and Australian approvals for Abbott’s investigational TAVI system.

Surgical Weekly Newsroom
Abbott initiates VOYAGER CE trial of Encantor TAVI system
Illustration: AI-generated

Abbott announced on November 19, 2026, that it had initiated VOYAGER CE, a clinical trial evaluating the safety and efficacy of its investigational Encantor transcatheter aortic valve implantation (TAVI) system. The software-guided, balloon-expandable platform targets symptomatic severe aortic stenosis, with the study intended to support approval applications in Europe and Australia.

VOYAGER CE begins enrollment in Sydney

The first enrollment occurred at Macquarie University in Sydney, Australia, led by Stephen Worthley, according to Abbott’s announcement. The provided excerpt of Abbott’s announcement does not specify the enrollment date.

Abbott’s November 19 study plan calls for up to 300 patients across Europe and Australia. The prospective, single-arm, pre-market trial will enroll patients with symptomatic severe aortic stenosis caused by severe calcium buildup in the aortic valve.

The enrollment marks the start of clinical execution for VOYAGER CE, rather than a regulatory decision. Abbott intends to use the study as the basis for seeking approval in both markets; Encantor remains investigational.

Software-guided balloon expansion

Encantor combines balloon-expandable valve technology with software-guided deployment. Abbott describes the software as designed to tailor valve expansion to individual patient anatomy, with precise implantation and consistent valve performance as development objectives. The provided announcement excerpt does not include clinical results demonstrating those benefits.

The expansion mechanism distinguishes Encantor from Abbott’s existing TAVI technology. According to MassDevice, the company’s current TAVI system uses a self-expanding valve. Encantor therefore adds a different deployment approach to Abbott’s development portfolio, rather than simply extending its self-expanding technology.

Abbott also said Encantor early feasibility study data would be presented at PCR London Valves 2026. That planned presentation concerns early feasibility work, while VOYAGER CE is the pre-market study intended to underpin the European and Australian approval applications.

What it means

For Abbott, Encantor creates a route toward offering both self-expanding and software-guided balloon-expandable TAVI technology. The immediate task is clinical: Abbott and participating investigators must execute the enrollment plan and evaluate safety and efficacy before the company can use VOYAGER CE to support its intended applications.

For the European and Australian markets, the relevant milestone is evidence generation, not commercial availability. First enrollment advances Encantor’s development, but it does not introduce an approved alternative for routine use.

The portfolio distinction also matters when assessing future competition. Encantor’s proposed differentiation rests on both its balloon-expandable mechanism and software-guided deployment. VOYAGER CE evaluates the investigational system in a single-arm study; it is not a head-to-head comparison with Abbott’s self-expanding technology or competing valves.

Author
Surgical Weekly Newsroom
The Surgical Weekly editorial team.